GlaxoSmithKline and Johnson & Johnson, which control most of the needed supplies for the industry, want authorities to approve genetic engineering so opium farming can be both expanded and made less susceptible to pests and so they can assure their customers they can keep up with demand.
After its competitor UPS settled with U.S. authorities over accusations that it was a key link in the supply chain for Internet pharmacies, FedEx vowed to fight any charges that came its way. It will get the chance to do just that after the Justice Department filed charges against the international delivery service.
The polar vortex that caused low temperatures in towns and cities across the eastern U.S. is now long gone, but its effects are still being felt. Having closed schools, roads and businesses over the winter, the cold weather has now been blamed by Bausch + Lomb for a recall of 880,000 tubes of eye ointment.
Sanofi has a plant in Saudi Arabia but had decided to expand its production capacity and reach in the Middle East market with an investment in an established company there. The drugmaker is taking control of Globalpharma, a decade-old company that sells products in the Middle East and Gulf Coast markets.
Biosimilars are expected to be a big revenue generator for the companies with the expertise and the facilities capable to produce them. mAbxience, a Swiss-based subsidiary of a Spanish company, says it intends to be among those and has bought a competitor in Spain to move those ambitions down the road.
Last week, drugmaker Hikma struck a deal to buy some of the sterile injectable assets of a Boehringer Ingelheim unit to expand in that growing part of the industry. Now, U.S.-based Amneal Pharmaceuticals is looking to India for a chance to exploit that niche of the market.
AMRI said the Albuquerque, NM-based Oso will expand its capabilities in small-molecule and biologics manufacturing.
Continuous manufacturing can reduce cycle times and make drug production more environmentally friendly, but it has yet to replace batch production in any significant way. Chemical & Engineering News revisited the benefits of continuous manufacturing and dug into why it has yet to take off in a feature this week.
Jubilant will use some of the cash to improve its generic drug manufacturing plants in India while also tapping the bank's emerging market healthcare expertise.
Over the past 18 months, India's SeQuent Scientific has won FDA approval of its API plant, sold its specialty chemicals business and acquired a stake in Shasun Pharma. The Bangalore-based business is maintaining the pace and further bolstering its API production business by agreeing to buy Arvee Synthesis.